Clinical Trials Browser

Leukemia, Myeloid, Acute

NCT04628026 2026-03-16

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Phase 3 Recruiting

650 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07469046 2026-03-13

VAH vs VA in Newly Diagnosed Elderly AML

Phase 3 Not yet recruiting

308 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03844048 2026-03-06

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

165 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

VENP-A-QUI

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

VAH vs VA in Newly Diagnosed Elderly AML

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

VAG-3+7-G

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

cAMeLot-2

VIALE-T

REGAL

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

VIALE-M

Viale-a

Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

ENHANCE-3

ENHANCE-2

Viale-a

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)